Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Community Fast Track, 2005
    Evaluation of the Role of Trace Amine 1 (TA1) Receptor in the Actions of Antiparkinsonian Drugs Using TA1 Receptor Knockout Mice

    One potential explanation of unprecedented efficacy of levodopa in the treatment of Parkinson's disease suggests that levodopa itself or its metabolites may affect targets in the brain in addition to...

  • Community Fast Track, 2005
    Role of corticostriatal neurons in provoking the imbalance between the direct and indirect striatal output pathways after dopamingergic degeration

    The striatum receives massive excitatory inputs from the cortex and is densely innervated by dopamine. Striatal projection neurons belong either to the direct or indirect pathways. Models of Parkinson...

  • Community Fast Track, 2005
    Pathogenesis of PD in alpha-synuclein cleavage by matrix metalloproteinase-3

    A recent finding from our research strongly indicates that matrix metalloproteinase-3 (MMP-3), a protein-cleaving enzyme, plays a pivotal role in degeneration of dopamine neurons in models of...

  • Community Fast Track, 2005
    Park8 Pre-clinical Models and LRRK2 Kinase Substrates

    LRRK2 is the most recent gene linked to PD and mutations in the gene represent one of the most common genetic causes of PD identified to date. However, little is known about the function of the LRRK2...

  • Community Fast Track, 2005
    Guidance of Midbrain Dopaminergic Neurons in Development and Disease

    A promising approach to alleviating the symptoms of Parkinson's disease is to transplant healthy dopaminergic neurons into the brains of these patients. Due to the large number of dopaminergic neurons...

  • Community Fast Track, 2005
    Specific Inhibition of Nucleation of Alpha-synuclein Aggregation As a Therapeutic Strategy

    The pathological hallmark of Parkinson's disease is the accumulation in nerve cells of dense clumps of aggregated protein. The clumps, called Lewy bodies, contain mostly a protein called alpha...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.